| 000 | 01901 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250516034653.0 | ||
| 264 | 0 | _c20110630 | |
| 008 | 201106s 0 0 eng d | ||
| 022 | _a0946-1965 | ||
| 024 | 7 |
_a10.5414/cp201507 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGraefe-Mody, E U | |
| 245 | 0 | 0 |
_aEffect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. _h[electronic resource] |
| 260 |
_bInternational journal of clinical pharmacology and therapeutics _cMay 2011 |
||
| 300 |
_a300-10 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnticoagulants _xpharmacokinetics |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xgenetics |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aChromatography, High Pressure Liquid |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2C9 |
| 650 | 0 | 4 |
_aDipeptidyl-Peptidase IV Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInternational Normalized Ratio |
| 650 | 0 | 4 | _aLinagliptin |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProthrombin Time |
| 650 | 0 | 4 |
_aPurines _xadverse effects |
| 650 | 0 | 4 |
_aQuinazolines _xadverse effects |
| 650 | 0 | 4 | _aSoftware |
| 650 | 0 | 4 | _aStereoisomerism |
| 650 | 0 | 4 | _aTandem Mass Spectrometry |
| 650 | 0 | 4 |
_aWarfarin _xpharmacokinetics |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aBrand, T | |
| 700 | 1 | _aRing, A | |
| 700 | 1 | _aWithopf, B | |
| 700 | 1 | _aStangier, J | |
| 700 | 1 | _aIovino, M | |
| 700 | 1 | _aWoerle, H-J | |
| 773 | 0 |
_tInternational journal of clinical pharmacology and therapeutics _gvol. 49 _gno. 5 _gp. 300-10 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.5414/cp201507 _zAvailable from publisher's website |
| 999 |
_c20806849 _d20806849 |
||